CollPlant Overview

October 2021

Safe harbor statement

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based BioInk, dermal fillers for aesthetics, breast implants, VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

Imagine a future where:

There will be an **unlimited supply** of spare parts for the human body, including life-saving organs

Drugs will be developed without the need for **animal testing**

Medical treatment will be **tailored** to the individual characteristics of each patient

CollPlant aims to play a major role in making it happen, helping people live longer and better



CollPlant – Unlocking the Regenerative Potential of rhCollagen

Regenerative and Aesthetic Medicine Company

Developing innovative technologies and products for tissue regeneration and organ manufacturing, to help people live longer and better

Proprietary Plant-based Technology Platform

Only commercially viable solution for mass production of rhCollagen

Collaboration Agreements with Industry Leaders

- AbbVie (ABBV)- Worldwide exclusive agreement for dermal and soft tissue fillers. Up to $103mm in payments plus royalties.
- 3D Systems (DDD)- Bioprinted solutions for breast reconstruction treatments

Well Capitalized

$48mm in cash and equivalents (June 30, 2021)

CollPlant
Pioneering Regenerative Medicine

Our body is made of collagen

~30% of body's protein content

Main structural protein in the extracellular matrix (e.g. cartilage, bones, tendons, ligaments, skin and vasculature)

Ideal scaffolding molecule for regenerative medicine



Transgenic tobacco plants

Expressing 5 human genes





CollPlant
Pioneering Regenerative Medicine

Plant-based platform produces human collagen in mass-scale

rhCollagen production process

Growing

Transgenic tobacco

Extraction

Crude extract

Purification

rhCollagen

Products

CollPlant
Pioneering Regenerative Medicine

rhCollagen- Ideal building block for tissue and organ transplants used in regenerative medicine

Clear advantages over tissue-extracted collagen

Better bio-functionality
- Accelerates human cell proliferation
- Faster tissue healing

Superior homogeneity
- Controlled physical/rheological properties
- Reproducibility
- Transparency (not visible)

Improved safety and greater purity
- Non-immunogenic
- Non-allergenic
- No pathogens
- No foreign body response

Plant-derived



Tissue Extracted



CollPlant
Revolutionizing Tissue Repair

Product Pipeline

Aesthetic medicine

Dermal/soft tissue fillers

Collaboration with Allergan an AbbVie company

Photocurable dermal filler

Injectable breast implants

Regenerative medicine

3D bioprinted products

Breast implants

Regenerative Tissue Matrix for breast reconstruction

3D SYSTEMS

BioInk formulations

Soft and hard tissues

CollPlant Pioneering Regenerative Medicine

Collagen platform drives diverse opportunities for value creation



* injectable, bioprinted and Regenerative Tissue Matrix

Dermal/Soft Tissue Fillers

Dermal fillers market overview

~2.2 M
HA procedures in 2019 in the US[1]

>$6.2B, 7.6% CAGR
Global dermal filler market, 2019[2] CAGR 2020-2026[2]

$100-$250/unit
Cost per syringe[3]

2019 Procedure breakdown, U.S (by material)[1]



1. https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf
2. https:// www.gminsights.com/industry-analysis/dermal-filler-market
3. https://www.medicalsparx.com/juvederm-hydrate , https://www.medicalsparx.com/buy-juvederm-ultra-plus-xc

CollPlant
Pioneering Regenerative Medicine

Collaboration agreement with AbbVie (Feb. 2021)

Agreement highlights:

A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market

Combines CollPlant's proprietary rhCollagen technology and AbbVie's technology

First right of negotiation for an injectable breast implant and photocurable dermal filler products

Financial highlights:

Up to $103M in potential payments, including:

- $14M upfront payment
- Up to $89M milestones and option payments

Royalties on products sales

CollPlant will manufacture and sell to AbbVie the rhCollagen used in the products

rhCollagen-based photocurable regenerative dermal filler key attributes

Easy injection (30G needle)



Injection

Sculpting before curing



Sculpting

Optimized post curing stiffness

Photocuring in-situ

Good tissue retention



Tissue regeneration

http://collplant.com/products/photocurable-dermal-filler-animation-video/

CollPlant
Pioneering Regenerative Medicine

Injectable breast implants*

- Composed of rhCollagen and additional materials, intended to promote breast tissue regeneration
- Designed to attract cells to promote tissue regeneration and support the viability and function of the newly regenerated tissue
- **The scaffold is designed to gradually degrade and be replaced by newly grown natural breast tissue that is free of any foreign material**

** AbbVie's Option Product*

3D Bioprinted Tissues and Organs

A great medical need for supply of life saving organs

~30,000
US transplants per year

115,000
US waiting list

900,000
US deaths per year from organ impairment

3D bioprinting expected to bridge this gap and allow unlimited supply of life saving organs

The technological building blocks already exist – a system integrator is needed to assemble them all together

CollPlant's rhCollagen-based BioInks portfolio and biomaterials expertise, are ideal for tissue and organ manufacturing

3D bioprinting represents a wide range of development opportunities



CollPlant
Pioneering Regenerative Medicine

rhCollagen BioInk compositions in development

ECM components
(biological/ physical properties)

Polymers
(physical properties)

Ceramics
(hard tissue)

Nanoparticles
(sustained release/
physical properties)

BioInk Components

3D Bioprinting technologies

Direct Ink Writing
(DIW)

Inkjet

Projection
Stereolithography

Laser Induced Forward
Transfer (LIFT)

CollPlant
Pioneering Regenerative Medicine

rhCollagen-based BioInks enable high resolution printing of elastic scaffolds





CollPlant
Pioneering Regenerative Medicine

Breast Reconstruction / Augmentation

Regenerative Tissue Matrix (RTM)

Developed in collaboration with 3D Systems

Provide extra coverage, direct-to-implant reconstruction and superior cosmetic results

US: mostly human-sourced (93%)
EU: mostly animal-sourced

Used in 61% of U.S. breast reconstruction surgeries

Breast reconstruction procedures using ADMS /yr (US): **60K**

Market potential (US) **$600Mn**

Surgical matrixes derived from cadavers and animals are associated with high costs, supply shortage and batch-to-batch variability

rhCollagen-based regenerative tissue matrix



CollPlant
Pioneering Regenerative Medicine

Breast implants market overview

Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it.

$1.4B Market
worldwide *(2018)*[1]

$ 5-10K Cost
per full procedure in US[2]

~2,500,000
Breast implant procedures WW *(2019)*[3]
~550,000 in US *(2019)*[4]

FDA alert: Patients with breast implants have an increased risk of developing breast implant Associated-Anaplastic Large Cell Lymphoma *(Feb 2019)*[5]



1. Analytical Research Cognizance, Global Breast Implant Market, March 2019
2. https://www.webmd.com/beauty/cosmetic-procedures-breast-augmentation#1
3. https://www.isaps.org/wp-content/uploads/2020/12/Global-Survey-2019.pdf
4. https://www.plasticsurgery.org/documents/News/Statistics/2019/plastic-surgery-statistics-full-report-2019.pdf\
5. https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-letter-health-care-providers

CollPlant
Pioneering Regenerative Medicine

CollPlant's 3D bioprinted breast implants



Breast scaffold bioprinting

rhCollagen + ECM* components

Implantation and vascularization

Implant replacement by newly formed tissue

* ECM- extracellular matrix

CollPlant
Pioneering Regenerative Medicine

Product pipeline

Product	Next milestone
 Dermal filler (AbbVie)	According to plan
 rhCollagen BioInks	1st BioInk market launch expected Q4, 2021
 Regenerative Tissue Matrix (with DDD)	Preclinical package
 Photocurable dermal filler	Preclinical package
 Injectable breast implant	Preclinical package
 Breast implants (3D printed)	Preclinical package

CollPlant
Pioneering Regenerative Medicine

Experienced management team

Yehiel Tal
CEO
Regentis Biomaterials
ProChon Biotech
Kulicke & Soffa Industries

Eran Rotem
Deputy CEO & CFO
Tefron, CFO (NYSE,TASE)
Healthcare Tech., CFO (NASDAQ) & Gamida
E&Y

Nadav Orr, PhD
VP R&D
Ethicon Biosurgery, Johnson & Johnson

Ilana Belzer, PhD
COO
BioHarvest
Procognia Ltd.
Omrix Biopharmaceuticals
Interpharm

Philippe Bensimon, PharmD
VP RA/QA/CA
Maquet Getinge
3M Medical

Hadas Dreiher-Horowitz
VP HR
Elbit
Teva Pharmaceuticals
Mul-T-Lock

CollPlant
Pioneering Regenerative Medicine

CollPlant investment thesis

- **Only commercially viable technology currently available that can produce truly human collagen**
- **Multi-billion dollar markets:** innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics
- **Broadly applicable technology:** Ideal building block/scaffolding molecule for regenerative medicine
- **Strategic agreement with AbbVie and 3D Systems**
- **Clinically validated technology**
- **Proven management team**


CollPlant
Biotechnologies
Pioneering
Regenerative
Medicine

Thank you